Voyager Therapeutics, Inc. VYGR
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a CNS/neurology/psychiatry drug developer. Its lead program, VY7523, is in Phase 1 for Alzheimer's disease (anti-tau antibody). Its next catalyst on record is VY7523: Initial tau PET imaging data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VY7523 — Initial tau PET imaging data (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VY7523 | Early AD | antibody | Phase 1 |
| VY1706 | Alzheimer's disease (AAV tau-silencing siRNA) | gene therapy | Phase 1 |
| NBIB-223 (FA program, Neurocrine) | Friedreich's ataxia | gene therapy | Pre-clinical |
| GBA1 program (Neurocrine) | Gaucher/Parkinson's | gene therapy | Pre-clinical |
| TDP-43 small molecules (Transition Bio) | ALS/FTD | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026n/a Robin Swartz appointed President of Voyager Therapeutics effective October 20, 2026.
On October 20, 2026 (the 'Effective Date'), the Board of Directors (the 'Board') of Voyager Therapeutics, Inc. (the 'Company') appointed Robin Swartz, the Company's Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective immediately.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.